Portfoliotracker

Revolution Medicines, Inc.

RVMD · NASDAQGS · Healthcare Biotechnology 0/100 E

166,87 $
▼ −5,42 (−3,15 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 11:44
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score0 / 100 Market cap35,9 mld. $ P/E– Forward P/E-53,8 P/S– P/B14,9 EV/EBITDA– Dividend yield– FCF yield-4,02 % EPS-8,92 $ Net margin0,0 % Return on equity-93,6 % Beta1,43 Debt / equity0,50
52-week range 67,27 to 224,31
3-month average volume2,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Website
revmed.com
Employees
883
Country
United States
Fiscal year end
31. 12.
Data since
13. 2. 2020

Explore further

Similar companies KYMRRLAYPCVXBBIOLEGN

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account